Concord Drugs
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
Get instant stock alerts
- Share Price
- Financials
- Revenue mix
- Shareholdings
- Peers
- Forensics
Share Price
Coming soon
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
Financials
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
| (In Cr.) |
|---|
| (In Cr.) | ||||
|---|---|---|---|---|
|
This data is currently unavailable for this company. |
| (In %) |
|---|
| (In Cr.) |
|---|
| Financial Year (In Cr.) |
|---|
Revenue mix
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Forensics
Recent events
-
News
-
Corporate Actions
June 27 (Reuters) - Concord Drugs Ltd CNCO.BO:
CONCORD DRUGS LTD - TEMPORARILY HOLDS FUNDRAISING AND CAPITAL INCREASE PROPOSAL
Source text: ID:nBSE1Cr0k1
Further company coverage: CNCO.BO
(([email protected];;))
June 27 (Reuters) - Concord Drugs Ltd CNCO.BO:
CONCORD DRUGS LTD - TEMPORARILY HOLDS FUNDRAISING AND CAPITAL INCREASE PROPOSAL
Source text: ID:nBSE1Cr0k1
Further company coverage: CNCO.BO
(([email protected];;))
March 17 (Reuters) - Concord Drugs Ltd CNCO.BO:
CONCORD DRUGS LTD - PUTS FUNDRAISING AND CAPITAL INCREASE ON HOLD
Source text: ID:nBSE3kVTZJ
Further company coverage: CNCO.BO
(([email protected];))
March 17 (Reuters) - Concord Drugs Ltd CNCO.BO:
CONCORD DRUGS LTD - PUTS FUNDRAISING AND CAPITAL INCREASE ON HOLD
Source text: ID:nBSE3kVTZJ
Further company coverage: CNCO.BO
(([email protected];))
March 4 (Reuters) - Concord Drugs Ltd CNCO.BO:
TO CONSIDER FUND RAISING
Source text: ID:nBSE50XYTc
Further company coverage: CNCO.BO
(([email protected];;))
March 4 (Reuters) - Concord Drugs Ltd CNCO.BO:
TO CONSIDER FUND RAISING
Source text: ID:nBSE50XYTc
Further company coverage: CNCO.BO
(([email protected];;))
More Nano Cap Ideas
See similar 'Nano' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
- Business
- Financials
- Share Price
- Shareholdings
What does Concord Drugs do?
Concord Drugs Limited, founded in 1995, is a leading pharmaceutical company in India. Specializing in generics, branded, and specialty pharmaceuticals, Concord is known for its diverse product portfolio of over 200 prescription and over-the-counter products.
Who are the competitors of Concord Drugs?
Concord Drugs major competitors are Tyche Industries, Godavari Drugs, Curis Lifesciences, Vaishali Pharma, Veerhealth Care, Pharmaids Pharma, Sotac Pharmaceutical. Market Cap of Concord Drugs is ₹107 Crs. While the median market cap of its peers are ₹107 Crs.
Is Concord Drugs financially stable compared to its competitors?
Concord Drugs seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Concord Drugs pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Concord Drugs latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Concord Drugs allocated its funds?
Companies resources are majorly tied in miscellaneous assets
How strong is Concord Drugs balance sheet?
Balance sheet of Concord Drugs is strong. But short term working capital might become an issue for this company.
Is the profitablity of Concord Drugs improving?
The profit is oscillating. The profit of Concord Drugs is ₹2.05 Crs for TTM, ₹0.34 Crs for Mar 2025 and ₹0.47 Crs for Mar 2024.
Is the debt of Concord Drugs increasing or decreasing?
The net debt of Concord Drugs is decreasing. Latest net debt of Concord Drugs is ₹12.85 Crs as of Mar-26. This is less than Mar-25 when it was ₹18.91 Crs.
Is Concord Drugs stock expensive?
Concord Drugs is expensive when considering the EV/EBIDTA, however latest PE is < 3 yr avg PE. Latest PE of Concord Drugs is 52.12, while 3 year average PE is 58.72. Also latest EV/EBITDA of Concord Drugs is 20.57 while 3yr average is 14.81.
Has the share price of Concord Drugs grown faster than its competition?
Concord Drugs has given better returns compared to its competitors. Concord Drugs has grown at ~31.28% over the last 3yrs while peers have grown at a median rate of -9.0%
Is the promoter bullish about Concord Drugs?
Promoters seem not to be bullish about the company and have been selling shares in the open market. Latest quarter promoter holding in Concord Drugs is 45.08% and last quarter promoter holding is 54.39%
Are mutual funds buying/selling Concord Drugs?
There is Insufficient data to gauge this.